Compare SOPH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | LUNG |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 63.6M |
| IPO Year | 2021 | 2020 |
| Metric | SOPH | LUNG |
|---|---|---|
| Price | $4.61 | $2.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $7.00 | $6.81 |
| AVG Volume (30 Days) | 100.5K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $73,297,000.00 | ★ $91,664,000.00 |
| Revenue This Year | $18.32 | $9.21 |
| Revenue Next Year | $15.61 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.66 | ★ 15.59 |
| 52 Week Low | $2.58 | $1.31 |
| 52 Week High | $5.30 | $9.37 |
| Indicator | SOPH | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 70.76 |
| Support Level | $4.54 | $1.96 |
| Resistance Level | $4.84 | $1.74 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 29.03 | 88.74 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.